Tyvaso Inhalant
Product Images NDC 66302-206

Product Visual Gallery

This gallery contains 100 technical images submitted to the FDA as part of the official labeling for Tyvaso (NDC 66302-206). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by United Therapeutics Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Tyvaso 01)

Chemical structure of treprostinil, the active ingredient in TYVASO inhalant, showing the arrangement of atoms and hydroxyl groups characteristic of its molecular structure.*

FDA Label Image

Figure 1 (Tyvaso 02)

A line chart comparing the percentage of patients experiencing a greater 6-minute walk distance (6MWD) change from baseline between Tyvaso (treprostinil inhalant) and placebo groups. The x-axis represents the 6MWD change in meters, ranging from -140 to 160, while the y-axis shows the percentage of patients. Two curves are shown: a solid line for Tyvaso (N=115) and a dashed line for placebo (N=120). Percentage differences at specific points, such as 32% and 52%, are marked on the graph.*

FDA Label Image

Figure 2 (Tyvaso 03)

A forest plot displaying placebo-corrected median treatment effects (in meters) for different subgroups in a clinical study comparing Tyvaso (treprostinil) inhalant to placebo. The chart includes sample sizes, age groups, gender, geographic regions, disease etiology, baseline 6-minute walk distance quartiles, and background therapies with corresponding treatment effect values and confidence intervals.*

FDA Label Image

Tyvaso 03a

A forest plot presenting placebo-corrected median treatment effects with 95% confidence intervals at different study visits for a treatment. The x-axis represents the placebo-corrected median treatment effect, while the y-axis lists time points including Week 4, 8, 12, 16, and Week 15 Trough. Each point estimate is marked with a red dot and corresponding horizontal lines indicate confidence intervals.*

FDA Label Image

Tyvaso 03b

A forest plot chart comparing the treatment effect of TYVASO (treprostinil inhalant) versus placebo across various patient subgroups. The chart includes categories based on age groups, sex, baseline 6-minute walk distance (6MWD), pulmonary hypertension etiology, baseline pulmonary vascular resistance (PVR), and maximum study drug dose breaths. Each subgroup shows hazard ratio estimates with 95% confidence intervals and p-values indicating statistical significance.*

FDA Label Image

Tyvaso 03c

A Kaplan-Meier survival curve chart showing the percentage of patients without an event over 16 weeks comparing TYVASO (treprostinil inhalant) and placebo groups. The x-axis represents time in weeks, and the y-axis represents patients without an event in percentage. The chart includes statistical data on p-values and hazard ratios, and a risk table shows the number of patients at risk in each group at various time points.*

FDA Label Image

Inhalation Device (Tyvaso 04)

A drug information panel titled "IMPORTANT" for TYVASO, emphasizing the need for training on the TYVASO Inhalation System before starting treatment. It advises patients to understand all directions and to consult healthcare providers with questions. It also states that TYVASO is only for use with its specific inhalation system.*

FDA Label Image

Figure (Tyvaso 05)

Illustration of the TYVASO inhalation device for treprostinil inhalant 1.74 mg/2.9 mL. The image highlights device features including a control light for inhalation, a multifunctional status light, a digital display showing breath counts and error messages, a START/STOP button to begin or pause treatment, and an ON/OFF button to switch power states.*

FDA Label Image

Figure (Tyvaso 06)

FDA Label Image

Figure (Tyvaso 07)

FDA Label Image

Figure (Tyvaso 08)

FDA Label Image

Figure (Tyvaso 09)

FDA Label Image

Figure (Tyvaso 10)

FDA Label Image

Figure (Tyvaso 100)

An illustration showing a medical inhalant device with a focus on two medicine cups labeled for clarity. The image highlights the presence and positioning of these two medicine cups, which are part of the device used for administering the inhalant drug TYVASO (treprostinil).*

FDA Label Image

Figure (Tyvaso 101)

An instructional illustration showing the assembly or parts of a filter membrane component labeled with "Open" and "Filter membrane." The transparent, cylindrical pieces connect together, demonstrating usage or installation steps.*

FDA Label Image

Figure (Tyvaso 102)

An instructional illustration showing the TYVASO inhalant device featuring two medicine cups. The image highlights the device's design with a close-up circle emphasizing the pair of medicine cups used for inhalation therapy.*

FDA Label Image

Figure (Tyvaso 103)

The image shows a close-up of the top portion of a clear plastic inhalant container with a white mouthpiece and a locking mechanism that includes a blue ring and a gray base. This container is associated with TYVASO (treprostinil) inhalant, 1.74 mg/2.9 mL, by United Therapeutics Corporation.*

FDA Label Image

Figure (Tyvaso 104)

TYVASO 1.74 mg/2.9 mL inhalant vial carton and clear glass vial label, with a green and white design. The label shows the proprietary name TYVASO, the active ingredient treprostinil, dosage form inhalant, and the labeler United Therapeutics Corporation. The vial appears to be a single-use sterile liquid medication container.*

FDA Label Image

Figure (Tyvaso 104a)

TYVASO 1.74 mg/2.9 mL inhalant label by United Therapeutics Corporation. The label includes the proprietary name TYVASO, generic name treprostinil, and indicates an oral inhalant dosage form. The product NDC 66302-206 is visible.*

FDA Label Image

Figure (Tyvaso 105)

Illustration of the front view of a TYVASO inhalation device showing labeled components including inhalation indicators at the top, a blue On/Off Start/Pause button in the middle, and a circular display screen below the button. The device is primarily blue and white in color.*

FDA Label Image

Figure (Tyvaso 106)

An illustration of the side view of a TYVASO inhalation device, showing the location and labels of the Run/Program button and Volume/Breaths control buttons on the blue and white device housing.*

FDA Label Image

Figure (Tyvaso 106a)

TYVASO 1.74 mg/2.9 mL inhalant, oral dosage form. The packaging shows a small transparent vial with clear liquid inside and white cap. The label on the vial displays the product name TYVASO and the strength 1.74 mg in 2.9 mL. The labeler is United Therapeutics Corporation.*

FDA Label Image

Figure (Tyvaso 107)

An illustration of the back view of a TYVASO treprostinil inhalant device showing the power port and power status indicators. The device is primarily blue and green with the TYVASO logo on the front panel.*

FDA Label Image

Figure (Tyvaso 108)

FDA Label Image

Figure (Tyvaso 109)

FDA Label Image

Figure (Tyvaso 11)

TYVASO inhalation system device in light blue color with a digital display showing breath count, start/stop and on/off buttons, and a label indicating use for prescription only. The device is used to administer treprostinil inhalant, with the labeler United Therapeutics Corporation. The system dosage is 1.74 mg/2.9 mL.*

FDA Label Image

Figure (Tyvaso 110)

TYVASO 1.74 mg/2.9 mL inhalant vial label showing the proprietary name TYVASO and the active ingredient treprostinil. The label includes dosage strength and volume information, as well as the labeler United Therapeutics Corporation. The vial is transparent with a white and green label design.*

FDA Label Image

Figure (Tyvaso 111)

FDA Label Image

Figure (Tyvaso 112)

FDA Label Image

Figure (Tyvaso 113)

FDA Label Image

Figure (Tyvaso 114)

TYVASO 1.74 mg/2.9 mL inhalant unit dose vial. The clear glass vial has a white label with black text showing the brand name TYVASO, strength 1.74 mg per 2.9 mL, and manufacturer United Therapeutics Corporation. The vial contains a clear liquid inhalant formulation for oral inhalation.*

FDA Label Image

Figure (Tyvaso 115)

FDA Label Image

Figure (Tyvaso 116)

TYVASO 1.74 mg/2.9 mL inhalant solution carton label from United Therapeutics Corporation. The label includes the product name, active ingredient treprostinil, strength, inhalant dosage form, route of administration (oral inhalation), and NDC number 66302-206. The packaging is primarily white and blue with detailed product information.*

FDA Label Image

Figure (Tyvaso 117)

TYVASO 1.74 mg/2.9 mL inhalant oral solution carton by United Therapeutics Corporation. The image shows the front panel labeled Rx Only, indicating prescription status.*

FDA Label Image

Figure (Tyvaso 118)

FDA Label Image

Figure (Tyvaso 119)

TYVASO 1.74 mg/2.9 mL inhalant bottle label by United Therapeutics Corporation. The label displays the proprietary name TYVASO prominently with the active ingredient treprostinil indicated. Dosage form is inhalant and package details appear on the label with the NDC 66302-206.*

FDA Label Image

Figure (Tyvaso 12)

An illustration showing a clear, cylindrical plastic device with an arrow and a notch indicating proper alignment or placement. It appears to be a component or accessory related to the administration of an inhalant product, possibly a spacer or holder for the TYVASO inhalant container.*

FDA Label Image

Figure (Tyvaso 120)

FDA Label Image

Figure (Tyvaso 121)

An instructional diagram displaying a circular timer indicating time since last treatment, showing 5 hours and 30 minutes. The timer is labeled 'Time since last treatment' with 'HR' and 'MIN' denoting hours and minutes respectively.*

FDA Label Image

Figure (Tyvaso 122)

An instructional circular diagram indicating a program setting of '9 Breaths' for an inhalant device, with 'Program' written above and the number '9' prominently displayed in the center followed by the word 'Breaths' below.*

FDA Label Image

Figure (Tyvaso 123)

FDA Label Image

Figure (Tyvaso 124)

An instructional graphic showing a circular indicator with the number '3' and the phrase 'Breaths left' above a battery icon, likely representing the remaining inhalations and device battery status for an inhalant medication.*

FDA Label Image

Figure (Tyvaso 125)

Instructional illustration showing a human head in profile exhaling, accompanied by the word 'Exhale' and a battery icon below, likely indicating guidance for inhalation use.*

FDA Label Image

Figure (Tyvaso 126)

An instructional illustration showing a person inhaling from an inhaler device. The image emphasizes the inhalation action, with visual cues including a profile of the head and the inhaler positioned at the mouth, accompanied by the word 'Inhale' and a battery indicator icon.*

FDA Label Image

Figure (Tyvaso 127)

TYVASO 1.74 mg/2.9 mL inhalant oral solution packaging label. The label includes the proprietary name TYVASO, generic name treprostinil, product strength, dosage form as inhalant, and states it is a prescription drug. The labeler is United Therapeutics Corporation with NDC 66302-206.*

FDA Label Image

Figure (Tyvaso 128)

An illustration showing a circular display screen with a black background. It features two vertical yellow bars and the word 'Paused' in yellow text below them. A battery icon with three green bars indicating charge is displayed at the bottom center.*

FDA Label Image

Figure (Tyvaso 129)

FDA Label Image

Figure (Tyvaso 13)

TYVASO 1.74 mg/2.9 mL inhalant sachet packaging by United Therapeutics Corporation. The image shows a partially opened foil pouch containing multiple individual plastic ampules for oral inhalation. The packaging appears for single-use liquid dose units of treprostinil inhalant.*

FDA Label Image

Figure (Tyvaso 130)

An instructional illustration showing various battery status icons and their meanings, including battery full, more than half full, less than half full, almost empty, charging, and an audio off icon indicating volume is all the way down.*

FDA Label Image

Figure (Tyvaso 131)

FDA Label Image

Figure (Tyvaso 132)

FDA Label Image

Figure (Tyvaso 133)

An instructional illustration showing the back of the TYVASO (treprostinil) inhalant device. Labeled parts include the power status, power port, and connector where the AC wall plug adapter is connected, with guidance to orient the flat edge of the plug facing up before inserting into a wall outlet.*

FDA Label Image

Figure (Tyvaso 134)

Illustration showing the control panel of a medical device with a digital display indicating '3 Breaths left' and a battery status icon. Below are four battery status indicators representing full, more than half full, less than half full, and almost empty battery levels. An inset highlights the device's switch with 'Run' and 'Program' labels and directional arrows.*

FDA Label Image

Figure (Tyvaso 135)

An instructional diagram showing the control panel of the TYVASO inhalant device, highlighting a switch with positions labeled 'Run' and 'Program' and a volume/brightness control dial with '+' and '-' markings.*

FDA Label Image

Figure (Tyvaso 136)

An instructional diagram showing a close-up of the control buttons on an inhalant device. The On/Off button is labeled and a circular display indicates the program breath count, showing 6 breaths with flashing numbers.*

FDA Label Image

Figure (Tyvaso 137)

An instructional diagram showing a control interface with a toggle switch marked with plus and minus signs to increase or decrease breaths. Beneath, a circular display labeled 'Program mode' indicates 'Program 3 Breaths.' This likely illustrates how to adjust breath settings on an inhalation device.*

FDA Label Image

Figure (Tyvaso 138)

Illustration showing the user interface of a TYVASO inhalant device. The top part shows a button labeled 'Run' and 'Program' with an arrow indicating operation. The bottom part displays a circular digital screen indicating 'Run mode,' number 3 breaths left, and a battery status icon.*

FDA Label Image

Figure (Tyvaso 139)

An illustration of the front view of an inhalant device, showing a blue On/Off switch button labeled accordingly and a large central circular feature likely part of the device's operational interface.*

FDA Label Image

Figure (Tyvaso 14)

Accessories for TYVASO (treprostinil) inhalant, including an AC wall plug, a rechargeable battery with attached cables and control, and a 12V DC adapter with coiled power cord. These components are likely part of the device kit used for administering the inhalant. Labeler is United Therapeutics Corporation.*

FDA Label Image

Figure (Tyvaso 140)

An instructional diagram showing a close-up of a control panel on a medical inhalant device labeled "Run" and "Program." The illustration highlights a button being pressed or moved, with an arrow indicating an upward motion to initiate the "Run" function. The device is predominantly white with blue and green accents.*

FDA Label Image

Figure (Tyvaso 141)

Illustration of a TYVASO inhalant device showing the control panel with an On/Off button and a digital display indicating '3 Breaths left.' A battery icon is also visible below the breaths count, representing the device's battery status.*

FDA Label Image

Figure (Tyvaso 142)

An instructional diagram showing a close-up view of a volume control interface with two buttons labeled '+' and '-'. The '+' button is indicated to increase volume, while the '-' button is indicated to decrease volume. The image uses arrows and text to demonstrate these functions.*

FDA Label Image

Figure (Tyvaso 143)

An illustration showing a circular icon labeled 'Adjust Volume' with a partial pie chart design and four vertical bars of increasing height, representing volume control.*

FDA Label Image

Figure (Tyvaso 144)

An instructional diagram icon showing a volume adjustment control symbolized by four ascending bar graph shapes within a circle, with the text 'Adjust Volume' above the bars on a blue background. This likely represents adjusting the dosage volume for an inhalant product.*

FDA Label Image

Figure (Tyvaso 145)

An illustration showing a circular icon divided horizontally with a blue upper half and white lower half. The upper half contains the text 'Adjust Volume' in white, and the lower half features four white bars of increasing height representing volume levels.*

FDA Label Image

Figure (Tyvaso 146)

Illustration of the On/Off button on an inhalant device for TYVASO (treprostinil) 1.74 mg/2.9 mL. The device is white with a blue upper section and a labeled On/Off button in the center area.*

FDA Label Image

Figure (Tyvaso 147)

An illustration showing hand washing technique with soap lathered on hands under running water, demonstrating proper hand hygiene.*

FDA Label Image

Figure (Tyvaso 148)

An illustration showing a TYVASO inhalation device with a power button and circular dial on the front. Next to it is a close-up view of the medication cartridge or dosing strip, partially inserted, labeled TYVASO. The image depicts the device and cartridge used for administering the treprostinil inhalant.*

FDA Label Image

Figure (Tyvaso 149)

An instructional diagram showing a gray inhalant device with two black arrows indicating a step or direction, meant to guide proper use or assembly of the device. No text or labels are visible on the illustration.*

FDA Label Image

Figure (Tyvaso 15)

TYVASO 1.74 mg/2.9 mL inhalant blister pack by United Therapeutics Corporation. The image shows a transparent plastic blister card containing 15 individual doses in a 3 by 5 arrangement. One dose is partially peeled back, revealing the container inside.*

FDA Label Image

Figure (Tyvaso 150)

TYVASO 1.74 mg/2.9 mL inhalant cartridge by United Therapeutics Corporation. The image shows a clear plastic inhalant cartridge designed for oral administration, with two separate circular white seals or filters beside it. No additional labeling or text visible on the cartridge.*

FDA Label Image

Figure (Tyvaso 151)

TYVASO 1.74 mg/2.9 mL inhalant blister pack by United Therapeutics Corporation. The image shows a rectangular blister containing 15 circular cavities arranged in a 3 by 5 grid. Each cavity appears to hold a single dose of the inhalant medication.*

FDA Label Image

Figure (Tyvaso 152)

An instructional diagram showing a close-up side view of a TYVASO inhalant mouthpiece or nebulizer component. The illustration highlights the shape and structure of the device's connection and tip used for oral inhalation of the treprostinil formulation.*

FDA Label Image

Figure (Tyvaso 153)

An illustration showing a clear inhaler mouthpiece with a rounded rectangular opening, depicted in a transparent view highlighting the internal design and shape of the oral inhalant device. No text or branding visible.*

FDA Label Image

Figure (Tyvaso 154)

An illustration showing a medical inhalation device component with a central tube and two side tubes, likely part of an inhalation system for pulmonary drug delivery.*

FDA Label Image

Figure (Tyvaso 155)

Illustration of two inhalation device components showing mouthpiece assemblies, likely parts of a TYVASO inhalant delivery system, used for administering treprostinil by oral inhalation.*

FDA Label Image

Figure (Tyvaso 156)

TYVASO inhalant 1.74 mg/2.9 mL packaging showing two clear inhalation vial containers with a top mouthpiece, each designed for oral inhalation. The labeler is United Therapeutics Corporation. The image depicts the vial dosage form used for delivering treprostinil via inhalation.*

FDA Label Image

Figure (Tyvaso 157)

TYVASO 1.74 mg/2.9 mL inhalant device in a black protective case with an attached strap and an inhaler mouthpiece visible on the side. The device is shown without external labeling or text.*

FDA Label Image

Figure (Tyvaso 158)

TYVASO 1.74 mg/2.9 mL inhalant in a clear vial with green and white labeling, manufactured by United Therapeutics Corporation. The label shows the product name TYVASO prominently along with the strength and formulation details. The vial is designed for oral inhalation use.*

FDA Label Image

Figure (Tyvaso 159)

TYVASO 1.74 mg/2.9 mL inhalant solution in a white plastic bottle with a gray and black cap, labeled by United Therapeutics Corporation. The bottle is designed for oral inhalation use.*

FDA Label Image

Figure (Tyvaso 16)

An illustration of a medical device component, likely a mouthpiece or inhaler part, with a clear plastic body and a blue internal piece. The image focuses on the top portion used for oral inhalation, corresponding to the TYVASO inhalant product.*

FDA Label Image

Figure (Tyvaso 160)

An illustration of a power adapter with a rectangular black body and a long attached cable ending in a connector plug. The adapter features two prongs for electrical outlet insertion and appears designed for use with a medical or electronic device.*

FDA Label Image

Figure (Tyvaso 161)

An instructional treatment tracker flyer for TYVASO (treprostinil) inhalant. The flyer includes an image of an inhalation device and the text emphasizes staying in step with treatments, with a section labeled "BREATHE IN" providing usage instructions and reminders. The United Therapeutics Corporation logo appears at the bottom.*

FDA Label Image

Figure (Tyvaso 162)

An instructional diagram showing a hand pouring liquid into a medical inhalant device water chamber. Labeled parts include the blue ring around the chamber, the target level fill line, the upper sensor near the top, and the water chamber itself. This image visually explains proper liquid filling for the device used with TYVASO inhalant.*

FDA Label Image

Figure (Tyvaso 163)

An instructional diagram showing a cross-section of a cylindrical inhalant device, labeled with parts identified as 'Cup' at the top and 'Bottom tip' near the base of the liquid chamber. The diagram likely illustrates the internal structure related to the delivery of the TYVASO inhalant, treprostinil 1.74 mg/2.9 mL.*

FDA Label Image

Figure (Tyvaso 164)

Packaging of TYVASO inhalant containing treprostinil at a strength of 1.74 mg/2.9 mL by United Therapeutics Corporation. The image shows a partially opened foil pouch with multiple ampules visible inside and a black rectangular tab labeled "Ampule".*

FDA Label Image

Figure (Tyvaso 165)

Illustration showing two hands demonstrating how to prepare the TYVASO inhalant device. The left panel shows a hand twisting the cap of the inhalant container with a green arrow indicating the rotation direction. The right panel shows a hand pulling the cap straight off the container with a green arrow indicating up and down motion.*

FDA Label Image

Figure (Tyvaso 166)

An instructional diagram showing a hand holding a small syringe labeled 'Squeeze' positioned above a container partially filled with liquid. The image illustrates the step of squeezing the syringe to deliver the liquid into the container, likely as part of preparing the TYVASO inhalant medication for administration.*

FDA Label Image

Figure (Tyvaso 167)

Illustration showing an inhalant device for administration of TYVASO (treprostinil) inhalant. The device includes a mouthpiece, control panel with a power button and program mode indicator, and tubing connectors for drug delivery.*

FDA Label Image

Figure (Tyvaso 168)

An instructional illustration showing a component of the TYVASO inhalant device. It highlights a black ring on the device's connector part, with a separated view of the threaded cap or attachment piece. The diagram focuses on the assembly or identification of these parts related to inhalant administration.*

FDA Label Image

Figure (Tyvaso 169)

An instructional diagram showing the proper assembly of the dome assembly onto the inhalant device for TYVASO (treprostinil). It highlights the start and end positions, indicating the dome assembly alignment with raised circles and filter shell port, viewed from front and back perspectives.*

FDA Label Image

Figure (Tyvaso 17)

TYVASO inhalant 1.74 mg/2.9mL by United Therapeutics Corporation. The image shows a clear plastic T-shaped connector piece, likely a component related to the inhalant delivery system. No text or packaging details are visible in the image.*

FDA Label Image

Figure (Tyvaso 170)

An instructional diagram showing how to open and close a component labeled with a filter membrane and filter shell. Arrows indicate the direction to turn for opening and closing the part, illustrating the mechanism of the filter component.*

FDA Label Image

Figure (Tyvaso 171)

An instructional diagram for the TYVASO (treprostinil) inhalant device showing the assembly of the filter shell with the inhalation piece. Labels indicate the filter shell port, filter shell, and inhalation piece, with arrows guiding the connection steps between these parts.*

FDA Label Image

Figure (Tyvaso 172)

An instructional diagram of the TYVASO inhalation device, showing the inhalation piece and filter shell components. The image highlights the setup for oral inhalation of the treprostinil inhalant medication.*

FDA Label Image

Figure (Tyvaso 173)

Illustration showing an inhalant device for TYVASO (treprostinil) with a labeled mouthpiece attachment. The device features control buttons on the front and an arrow indicating where the mouthpiece connects.*

FDA Label Image

Figure (Tyvaso 174)

An instructional diagram of a TYVASO inhalant device showing the inhalation piece and the display screen. The inhalation piece is at the top, connected to the main body of the device, which houses the display screen for patient use.*

FDA Label Image

Figure (Tyvaso 175)

An instructional illustration showing a digital display screen of the TYVASO inhalation system. The screen indicates the time since last treatment as 05 hours and 30 minutes, and the number of breaths left as 7. Battery status icon is also visible.*

FDA Label Image

Figure (Tyvaso 176)

An illustrated diagram of the TYVASO inhalation device showing its on/off button and a digital display indicating the number of breaths left (3) along with a battery icon. The device design includes a blue and white color scheme with labeled functional parts for user guidance.*

FDA Label Image

Figure (Tyvaso 177)

Illustration showing the back of a TYVASO (treprostinil) inhalant device with labeled components including power status, power port, and connector. It demonstrates how to connect the device to an AC wall plug, with a close-up detail of the connector orientation featuring a flat edge facing up.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.